Top

Reviews in Endocrine and Metabolic Disorders

Published in:

01-12-2008

New insights into the mechanisms of fibrosis and sclerosis in diabetic nephropathy

Author: Frank C. Brosius III

Published in: Reviews in Endocrine and Metabolic Disorders | Issue 4/2008

Abstract

Progression of diabetic nephropathy (DN) is manifested by gradual scarring of both the renal glomerulus and tubulointerstitial region. Over the past several years, the general understanding of the pathogenic factors that lead to renal fibrosis in DN has expanded considerably. In this review, some of the important factors that appear to be involved in driving this fibrosing process are discussed, with special emphasis on newer findings and insights. It is now clear that multiple cell types in the kidney contribute to progressive fibrosis in DN. New concepts about bradykinin, TGF-β and eNOS signaling as well as JAK/STAT activation and the central role of inflammation in both glomerular and tubulointerstitial fibrosis are discussed.

Alsaad KO, Herzenberg AM. Distinguishing diabetic nephropathy from other causes of glomerulosclerosis: an update. J Clin Pathol 2007;60:18–26. doi:10.1136/jcp.2005.035592.PubMedCrossRef

Mason RM, Wahab NA. Extracellular matrix metabolism in diabetic nephropathy. J Am Soc Nephrol 2003;14:1358–73. doi:10.1097/01.ASN.0000065640.77499.D7.PubMedCrossRef

Chen S, Jim B, Ziyadeh FN. Diabetic nephropathy and transforming growth factor-beta: transforming our view of glomerulosclerosis and fibrosis build-up. Semin Nephrol 2003;23:532–43. doi:10.1053/S0270–9295(03)00132–3.PubMedCrossRef

Mauer SM, Steffes MW, Ellis EN, Sutherland DE, Brown DM, Goetz FC. Structural-functional relationships in diabetic nephropathy. J Clin Invest 1984;74:1143–55. doi:10.1172/JCI111523.PubMedCrossRef

Bader R, Bader H, Grund KE, Mackensen-Haen S, Christ H, Bohle A. Structure and function of the kidney in diabetic glomerulosclerosis. Correlations between morphological and functional parameters. Pathol Res Pract 1980;167:204–16.PubMed

Fioretto P, Mauer M. Histopathology of diabetic nephropathy. Semin Nephrol 2007;27:195–207. doi:10.1016/j.semnephrol.2007.01.012.PubMedCrossRef

Katz A, Caramori ML, Sisson-Ross S, Groppoli T, Basgen JM, Mauer M. An increase in the cell component of the cortical interstitium antedates interstitial fibrosis in type 1 diabetic patients. Kidney Int 2002;61:2058–66. doi:10.1046/j.1523-1755.2002.00370.x.PubMedCrossRef

Wharram BL, Goyal M, Wiggins JE, et al. Podocyte depletion causes glomerulosclerosis: diphtheria toxin-induced podocyte depletion in rats expressing human diphtheria toxin receptor transgene. J Am Soc Nephrol 2005;16:2941–52. doi:10.1681/ASN.2005010055.PubMedCrossRef

Pagtalunan ME, Miller PL, Jumping-Eagle S, et al. Podocyte loss and progressive glomerular injury in type II diabetes. J Clin Invest 1997;99:342–8. doi:10.1172/JCI119163.PubMedCrossRef

10.

Meyer TW, Bennett PH, Nelson RG. Podocyte number predicts long-term urinary albumin excretion in Pima Indians with Type II diabetes and microalbuminuria. Diabetologia 1999;42:1341–4. doi:10.1007/s001250051447.PubMedCrossRef

11.

Morcos M, Borcea V, Isermann B, et al. Effect of alpha-lipoic acid on the progression of endothelial cell damage and albuminuria in patients with diabetes mellitus: an exploratory study. Diabetes Res Clin Pract 2001;52:175–83. doi:10.1016/S0168-8227(01)00223-6.PubMedCrossRef

12.

Isermann B, Vinnikov IA, Madhusudhan T, et al. Activated protein C protects against diabetic nephropathy by inhibiting endothelial and podocyte apoptosis. Nat Med 2007;13:1349–58. doi:10.1038/nm1667.PubMedCrossRef

13.

Zhao HJ, Wang S, Cheng H, et al. Endothelial nitric oxide synthase deficiency produces accelerated nephropathy in diabetic mice. J Am Soc Nephrol 2006;17:2664–9. doi:10.1681/ASN.2006070798.PubMedCrossRef

14.

Nakagawa T, Sato W, Glushakova O, et al. Diabetic endothelial nitric oxide synthase knockout mice develop advanced diabetic nephropathy. J Am Soc Nephrol 2007;18:539–50. doi:10.1681/ASN.2006050459.PubMedCrossRef

15.

Toyoda M, Najafian B, Kim Y, Caramori ML, Mauer M. Podocyte detachment and reduced glomerular capillary endothelial fenestration in human type 1 diabetic nephropathy. Diabetes 2007;56:2155–60.PubMedCrossRef

16.

Oldfield MD, Bach LA, Forbes JM, et al. Advanced glycation end products cause epithelial-myofibroblast transdifferentiation via the receptor for advanced glycation end products (RAGE). J Clin Invest 2001;108:1853–63.PubMed

17.

Burns WC, Twigg SM, Forbes JM, et al. Connective tissue growth factor plays an important role in advanced glycation end product-induced tubular epithelial-to-mesenchymal transition: implications for diabetic renal disease. J Am Soc Nephrol 2006;17:2484–94. doi:10.1681/ASN.2006050525.PubMedCrossRef

18.

Thomas MC, Burns WC, Cooper ME. Tubular changes in early diabetic nephropathy. Adv Chronic Kidney Dis 2005;12:177–86. doi:10.1053/j.ackd.2005.01.008.PubMedCrossRef

19.

Pedagogos E, Hewitson T, Fraser I, Nicholls K, Becker G. Myofibroblasts and arteriolar sclerosis in human diabetic nephropathy. Am J Kidney Dis 1997;29:912–8. doi:10.1016/S0272-6386(97)90466-2.PubMedCrossRef

20.

Zoja C, Donadelli R, Colleoni S, et al. Protein overload stimulates RANTES production by proximal tubular cells depending on NF-kappa B activation. Kidney Int 1998;53:1608–15. doi:10.1046/j.1523-1755.1998.00905.x.PubMedCrossRef

21.

Tang S, Leung JC, Abe K, et al. Albumin stimulates interleukin-8 expression in proximal tubular epithelial cells in vitro and in vivo. J Clin Invest 2003;111:515–27.PubMed

22.

Eddy AA, Kim H, Lopez-Guisa J, Oda T, Soloway PD. Interstitial fibrosis in mice with overload proteinuria: deficiency of TIMP-1 is not protective. Kidney Int 2000;58:618–28. doi:10.1046/j.1523-1755.2000.00208.x.PubMedCrossRef

23.

Eddy AA, Giachelli CM. Renal expression of genes that promote interstitial inflammation and fibrosis in rats with protein-overload proteinuria. Kidney Int 1995;47:1546–57. doi:10.1038/ki.1995.218.PubMedCrossRef

24.

Wang Y, Chen J, Chen L, Tay YC, Rangan GK, Harris DC. Induction of monocyte chemoattractant protein-1 in proximal tubule cells by urinary protein. J Am Soc Nephrol 1997;8:1537–45.PubMed

25.

Zheng F, Cornacchia F, Schulman I, et al. Development of albuminuria and glomerular lesions in normoglycemic B6 recipients of db/db mice bone marrow: the role of mesangial cell progenitors. Diabetes 2004;53:2420–7. doi:10.2337/diabetes.53.9.2420.PubMedCrossRef

26.

Chow F, Ozols E, Nikolic-Paterson DJ, Atkins RC, Tesch GH. Macrophages in mouse type 2 diabetic nephropathy: correlation with diabetic state and progressive renal injury. Kidney Int 2004;65:116–28. doi:10.1111/j.1523-1755.2004.00367.x.PubMedCrossRef

27.

Okada S, Shikata K, Matsuda M, et al. Intercellular adhesion molecule-1-deficient mice are resistant against renal injury after induction of diabetes. Diabetes 2003;52:2586–93. doi:10.2337/diabetes.52.10.2586.PubMedCrossRef

28.

Levine DZ. Can rodent models of diabetic kidney disease clarify the significance of early hyperfiltration?: recognizing clinical and experimental uncertainties. Clin Sci (Lond) 2008;114:109–18. doi:10.1042/CS20070088.

29.

Gurley SB, Coffman TM. The renin-angiotensin system and diabetic nephropathy. Semin Nephrol 2007;27:144–52. doi:10.1016/j.semnephrol.2007.01.009.PubMedCrossRef

30.

Gnudi L, Thomas SM, Viberti G. Mechanical forces in diabetic kidney disease: a trigger for impaired glucose metabolism. J Am Soc Nephrol 2007;18:2226–32. doi:10.1681/ASN.2006121362.PubMedCrossRef

31.

Heilig CW, Liu Y, England RL, et al. D-glucose stimulates mesangial cell GLUT1 expression and basal and IGF-I-sensitive glucose uptake in rat mesangial cells: implications for diabetic nephropathy. Diabetes 1997;46:1030–9. doi:10.2337/diabetes.46.6.1030.PubMedCrossRef

32.

D’Agord Schaan B, Lacchini S, Bertoluci MC, Irigoyen MC, Machado UF, Schmid H. Increased renal GLUT1 abundance and urinary TGF-beta 1 in streptozotocin-induced diabetic rats: implications for the development of nephropathy complicating diabetes. Hormone and metabolic research. Horm Metab Res 2001;33:664–9.PubMedCrossRef

33.

Horie K, Miyata T, Maeda K, et al. Immunohistochemical colocalization of glycoxidation products and lipid peroxidation products in diabetic renal glomerular lesions. Implication for glycoxidative stress in the pathogenesis of diabetic nephropathy. J Clin Invest 1997;100:2995–3004. doi:10.1172/JCI119853.PubMedCrossRef

34.

Skolnik EY, Yang Z, Makita Z, Radoff S, Kirstein M, Vlassara H. Human and rat mesangial cell receptors for glucose-modified proteins: potential role in kidney tissue remodelling and diabetic nephropathy. J Exp Med 1991;174:931–9. doi:10.1084/jem.174.4.931.PubMedCrossRef

35.

Makita Z, Radoff S, Rayfield EJ, et al. Advanced glycosylation end products in patients with diabetic nephropathy. N Engl J Med 1991;325:836–42.PubMed

36.

Derubertis FR, Craven PA. Activation of protein kinase C in glomerular cells in diabetes. Mechanisms and potential links to the pathogenesis of diabetic glomerulopathy. Diabetes 1994;43:1–8. doi:10.2337/diabetes.43.1.1.PubMedCrossRef

37.

Babazono T, Kapor-Drezgic J, Dlugosz JA, Whiteside C. Altered expression and subcellular localization of diacylglycerol-sensitive protein kinase C isoforms in diabetic rat glomerular cells. Diabetes 1998;47:668–76. doi:10.2337/diabetes.47.4.668.PubMedCrossRef

38.

Yamamoto T, Nakamura T, Noble NA, Ruoslahti E, Border WA. Expression of transforming growth factor beta is elevated in human and experimental diabetic nephropathy. Proc Natl Acad Sci U S A 1993;90:1814–8. doi:10.1073/pnas.90.5.1814.PubMedCrossRef

39.

Ziyadeh FN, Sharma K, Ericksen M, Wolf G. Stimulation of collagen gene expression and protein synthesis in murine mesangial cells by high glucose is mediated by autocrine activation of transforming growth factor-beta. J Clin Invest 1994;93:536–42. doi:10.1172/JCI117004.PubMedCrossRef

40.

Marre M, Bernadet P, Gallois Y, et al. Relationships between angiotensin I converting enzyme gene polymorphism, plasma levels, and diabetic retinal and renal complications. Diabetes 1994;43:384–8. doi:10.2337/diabetes.43.3.384.PubMedCrossRef

41.

Doria A, Warram JH, Krolewski AS. Genetic predisposition to diabetic nephropathy. Evidence for a role of the angiotensin I-converting enzyme gene. Diabetes 1994;43:690–5. doi:10.2337/diabetes.43.5.690.PubMedCrossRef

42.

Huang W, Gallois Y, Bouby N, et al. Genetically increased angiotensin I-converting enzyme level and renal complications in the diabetic mouse. Proc Natl Acad Sci U S A 2001;98:13330–4. doi:10.1073/pnas.231476798.PubMedCrossRef

43.

Takahashi N, Hagaman JR, Kim HS, Smithies O. Minireview: computer simulations of blood pressure regulation by the rennin–angiotensin system. Endocrinology 2003;144:2184–90. doi:10.1210/en.2002-221045.PubMedCrossRef

44.

Kakoki M, Takahashi N, Jennette JC, Smithies O. Diabetic nephropathy is markedly enhanced in mice lacking the bradykinin B2 receptor. Proc Natl Acad Sci USA 2004;101:13302–5. doi:10.1073/pnas.0405449101.PubMedCrossRef

45.

Kakoki M, Kizer CM, Yi X, et al. Senescence-associated phenotypes in Akita diabetic mice are enhanced by absence of bradykinin B2 receptors. J Clin Invest 2006;116:1302–9. doi:10.1172/JCI26958.PubMedCrossRef

46.

Allard J, Buleon M, Cellier E, et al. ACE inhibitor reduces growth factor receptor expression and signaling but also albuminuria through B2-kinin glomerular receptor activation in diabetic rats. Am J Physiol Renal Physiol 2007;293:F1083–92. doi:10.1152/ajprenal.00401.2006.PubMedCrossRef

47.

Hirano T, Kashiwazaki K, Moritomo Y, Nagano S, Adachi M. Albuminuria is directly associated with increased plasma PAI-1 and factor VII levels in NIDDM patients. Diabetes Res Clin Pract 1997;36:11–8. doi:10.1016/S0168-8227(97)01384-3.PubMedCrossRef

48.

Nicholas SB, Aguiniga E, Ren Y, et al. Plasminogen activator inhibitor-1 deficiency retards diabetic nephropathy. Kidney Int 2005;67:1297–307. doi:10.1111/j.1523-1755.2005.00207.x.PubMedCrossRef

49.

Huang Y, Border WA, Yu L, Zhang J, Lawrence DA, Noble NAA. PAI-1 mutant, PAI-1R, slows progression of diabetic nephropathy. J Am Soc Nephrol 2008;19:329–38. doi:10.1681/ASN.2007040510.PubMedCrossRef

50.

Leiter LA. The prevention of diabetic microvascular complications of diabetes: is there a role for lipid lowering. Diabetes Res Clin Pract 2005;68(Suppl 2):S3–S14. doi:10.1016/j.diabres.2005.03.015.PubMedCrossRef

51.

Proctor G, Jiang T, Iwahashi M, Wang Z, Li J, Levi M. Regulation of renal fatty acid and cholesterol metabolism, inflammation, and fibrosis in Akita and OVE26 mice with type 1 diabetes. Diabetes 2006;55:2502–9. doi:10.2337/db05-0603.PubMedCrossRef

52.

Sun L, Halaihel N, Zhang W, Rogers T, Levi M. Role of sterol regulatory element-binding protein 1 in regulation of renal lipid metabolism and glomerulosclerosis in diabetes mellitus. J Biol Chem 2002;277:18919–27. doi:10.1074/jbc.M110650200.PubMedCrossRef

53.

Jiang T, Wang XX, Scherzer P, et al. Farnesoid X receptor modulates renal lipid metabolism, fibrosis, and diabetic nephropathy. Diabetes 2007;56:2485–93. doi:10.2337/db06-1642.PubMedCrossRef

54.

Hao CM, Breyer MD. Roles of lipid mediators in kidney injury. Semin Nephrol 2007;27:338–51.PubMedCrossRef

55.

Komers R, Lindsley JN, Oyama TT, Anderson S. Cyclo-oxygenase-2 inhibition attenuates the progression of nephropathy in uninephrectomized diabetic rats. Clin Exp Pharmacol Physiol 2007;34:36–41. doi:10.1111/j.1440-1681.2007.04534.x.PubMedCrossRef

56.

Cheng HF, Wang CJ, Moeckel GW, Zhang MZ, McKanna JA, Harris RC. Cyclooxygenase-2 inhibitor blocks expression of mediators of renal injury in a model of diabetes and hypertension. Kidney Int 2002;62:929–39. doi:10.1046/j.1523-1755.2002.00520.x.PubMedCrossRef

57.

Sassen S, Miska EA, Caldas C. MicroRNA-implications for cancer. Virchows Arch 2008;452:1–10.PubMedCrossRef

58.

Kato M, Zhang J, Wang M, et al. MicroRNA-192 in diabetic kidney glomeruli and its function in TGF-beta-induced collagen expression via inhibition of E-box repressors. Proc Natl Acad Sci USA 2007;104:3432–7. doi:10.1073/pnas.0611192104.PubMedCrossRef

59.

Fujiwara Y, Tagami S, Kawakami Y. Circulating thrombomodulin and hematological alterations in type 2 diabetic patients with retinopathy. J Atheroscler Thromb 1998;5:21–8.PubMed

60.

Amiri F, Shaw S, Wang X, et al. Angiotensin II activation of the JAK/STAT pathway in mesangial cells is altered by high glucose. Kidney Int 2002;61:1605–16. doi:10.1046/j.1523-1755.2002.00311.x.PubMedCrossRef

61.

Banes AK, Shaw S, Jenkins J, et al. Angiotensin II blockade prevents hyperglycemia-induced activation of JAK and STAT proteins in diabetic rat kidney glomeruli. Am J Physiol Renal Physiol 2004;286:F653–9. doi:10.1152/ajprenal.00163.2003.PubMedCrossRef

62.

Marrero MB, Banes-Berceli AK, Stern DM, Eaton DC. Role of the JAK/STAT signaling pathway in diabetic nephropathy. Am J Physiol Renal Physiol 2006;290:F762–F8. doi:10.1152/ajprenal.00181.2005.PubMedCrossRef

63.

Boucherot AHA, Cohen CD, Schin ML, Burke K, Bayer I, Schmid HRM, et al. Jak/Stat activation in diabetic nephropathy in humans but not mice: transcriptional analysis. J Am Soc Nephrol 2006;17:60A.

64.

Logar CM, Brinkkoetter PT, Krofft RD, Pippin JW, Shankland SJ. Darbepoetin alfa protects podocytes from apoptosis in vitro and in vivo. Kidney Int 2007;72:489–98. doi:10.1038/sj.ki.5002362.PubMedCrossRef

65.

Dalla Vestra M, Mussap M, Gallina P, et al. Acute-phase markers of inflammation and glomerular structure in patients with type 2 diabetes. J Am Soc Nephrol 2005;16(Suppl 1):S78–82. doi:10.1681/ASN.2004110961.PubMedCrossRef

66.

Stehouwer CD, Gall MA, Twisk JW, Knudsen E, Emeis JJ, Parving HH. Increased urinary albumin excretion, endothelial dysfunction, and chronic low-grade inflammation in type 2 diabetes: progressive, interrelated, and independently associated with risk of death. Diabetes 2002;51:1157–65. doi:10.2337/diabetes.51.4.1157.PubMedCrossRef

67.

Wolkow PP, Niewczas MA, Perkins B, et al. Association of urinary inflammatory markers and renal decline in microalbuminuric type 1 diabetics. J Am Soc Nephrol 2008;19:789–97. doi:10.1681/ASN.2007050556.PubMedCrossRef

68.

Schmid H, Boucherot A, Yasuda Y, et al. Modular activation of nuclear factor-kappaB transcriptional programs in human diabetic nephropathy. Diabetes 2006;55:2993–3003. doi:10.2337/db06-0477.PubMedCrossRef

69.

Navarro JF, Milena FJ, Mora C, Leon C, Garcia J. Renal pro-inflammatory cytokine gene expression in diabetic nephropathy: effect of angiotensin-converting enzyme inhibition and pentoxifylline administration. Am J Nephrol 2006;26:562–70. doi:10.1159/000098004.PubMedCrossRef

70.

Chow FY, Nikolic-Paterson DJ, Atkins RC, Tesch GH. Macrophages in streptozotocin-induced diabetic nephropathy: potential role in renal fibrosis. Nephrol Dial Transplant 2004;19:2987–96. doi:10.1093/ndt/gfh441.PubMedCrossRef

71.

Tesch GH. Role of macrophages in complications of type 2 diabetes. Clin Exp Pharmacol Physiol 2007;34:1016–9. doi:10.1111/j.1440-1681.2007.04729.x.PubMedCrossRef

72.

Usui HK, Shikata K, Sasaki M, et al. Macrophage scavenger receptor-a-deficient mice are resistant against diabetic nephropathy through amelioration of microinflammation. Diabetes 2007;56:363–72. doi:10.2337/db06-0359.PubMedCrossRef

73.

Yozai K, Shikata K, Sasaki M, et al. Methotrexate prevents renal injury in experimental diabetic rats via anti-inflammatory actions. J Am Soc Nephrol 2005;16:3326–38. doi:10.1681/ASN.2004111011.PubMedCrossRef

74.

Furuta T, Saito T, Ootaka T, et al. The role of macrophages in diabetic glomerulosclerosis. Am J Kidney Dis 1993;21:480–5.PubMed

75.

Chow FY, Nikolic-Paterson DJ, Ozols E, Atkins RC, Tesch GH. Intercellular adhesion molecule-1 deficiency is protective against nephropathy in type 2 diabetic db/db mice. J Am Soc Nephrol 2005;16:1711–22. doi:10.1681/ASN.2004070612.PubMedCrossRef

76.

Wong CK, Ho AW, Tong PC, et al. Aberrant activation profile of cytokines and mitogen-activated protein kinases in type 2 diabetic patients with nephropathy. Clin Exp Immunol 2007;149:123–31.PubMed

77.

Awad AS, Huang L, Ye H, et al. Adenosine A2A receptor activation attenuates inflammation and injury in diabetic nephropathy. Am J Physiol Renal Physiol 2006;290:F828–37. doi:10.1152/ajprenal.00310.2005.PubMedCrossRef

78.

Mizuno M, Sada T, Kato M, Fukushima Y, Terashima H, Koike H. The effect of angiotensin II receptor blockade on an end-stage renal failure model of type 2 diabetes. J Cardiovasc Pharmacol 2006;48:135–42. doi:10.1097/01.fjc.0000245241.79959.d6.PubMedCrossRef

79.

Agarwal R. Anti-inflammatory effects of short-term pioglitazone therapy in men with advanced diabetic nephropathy. Am J Physiol Renal Physiol 2006;290:F600–5. doi:10.1152/ajprenal.00289.2005.PubMedCrossRef

80.

Chander PN, Gealekman O, Brodsky SV, et al. Nephropathy in Zucker diabetic fat rat is associated with oxidative and nitrosative stress: prevention by chronic therapy with a peroxynitrite scavenger ebselen. J Am Soc Nephrol 2004;15:2391–403. doi:10.1097/01.ASN.0000135971.88164.2C.PubMedCrossRef

Title: New insights into the mechanisms of fibrosis and sclerosis in diabetic nephropathy
Author: Frank C. Brosius III
Publication date: 01-12-2008
Publisher: Springer US
Published in: Reviews in Endocrine and Metabolic Disorders / Issue 4/2008
Print ISSN: 1389-9155
Electronic ISSN: 1573-2606
DOI: https://doi.org/10.1007/s11154-008-9100-6

Live Webinar | 27-06-2024 | 18:00 (CEST)

Keynote webinar | Spotlight on medication adherence

Reserve your place

Live: Thursday 27th June 2024, 18:00-19:30 (CEST)

WHO estimates that half of all patients worldwide are non-adherent to their prescribed medication. The consequences of poor adherence can be catastrophic, on both the individual and population level.

Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.

Prof. Kevin Dolgin

Prof. Florian Limbourg

Prof. Anoop Chauhan

Developed by: Springer Medicine

Obesity Clinical Trial Summary

At a glance: The STEP trials

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.

Developed by: Springer Medicine

Highlights from the ACC 2024 Congress

Year in Review: Pediatric cardiology

Pediatric Cardiology Video

Watch Dr. Anne Marie Valente present the last year's highlights in pediatric and congenital heart disease in the official ACC.24 Year in Review session.

Year in Review: Pulmonary vascular disease

Cardiopulmonary Comorbidity Video

The last year's highlights in pulmonary vascular disease are presented by Dr. Jane Leopold in this official video from ACC.24.

Year in Review: Valvular heart disease

Valvular Heart Disease Video

Watch Prof. William Zoghbi present the last year's highlights in valvular heart disease from the official ACC.24 Year in Review session.

Year in Review: Heart failure and cardiomyopathies

Heart Failure Video

Watch this official video from ACC.24. Dr. Biykem Bozkurt discusses last year's major advances in heart failure and cardiomyopathies.

ACC 2024 Congress Coverage

Year in Review: Heart failure and cardiomyopathies

Heart Failure Video

Watch this official video from ACC.24. Dr. Biykem Bozkurt discusses last year's major advances in heart failure and cardiomyopathies.

Watch now

Semaglutide benefits people with type 2 diabetes and obesity-related heart failure

16-04-2024 Type 2 Diabetes News

Incentivised to exercise

11-04-2024 Lifestyle Modifications News

New intervention for STEMI-related cardiogenic shock

10-04-2024 Myocardial Infarction News

» View more highlights on the ACC 2024 congress hub page

Image Credits

Illustration of figure on mountain summit/© Orapun / Stock.adobe.com, STEP AAG HeroTeaserCollection image/© Tarek / Generated with AI / Stock.adobe.com, ACC 2024 Pediatric and Congenital Heart Disease: Year in Review/© 2024 American College of Cardiology, ACC 2024 Pulmonary Vascular Disease: Year in Review/© 2024 American College of Cardiology, ACC 2024 Valvular Heart Disease: Year in Review/© 2024 American College of Cardiology, ACC 2024 HF and Cardiomyopathies: Year in Review/© 2024 American College of Cardiology, Woman out walking/© Seventyfour / stock.adobe.com (symbolic image with model), Woman checking smartwatch /© saltdium / stock.adobe.com (symbolic image with model), Cardiac catheterization/© Damian / stock.adobe.com

Keynote webinar | Spotlight on medication adherence

Springer Medicine

Abstract

Please log in to get access to this content

Other articles of this Issue 4/2008

Proteoglycan mediated lipoprotein retention: A mechanism of diabetic atherosclerosis

Mass spectrometric quantification of amino acid oxidation products identifies oxidative mechanisms of diabetic end-organ damage

Oxidative stress and diabetic retinopathy: Pathophysiological mechanisms and treatment perspectives

Defining human diabetic nephropathy on the molecular level: Integration of transcriptomic profiles with biological knowledge

Novel mechanisms of protein synthesis in diabetic nephropathy—role of mRNA translation

Mechanisms of disease: The oxidative stress theory of diabetic neuropathy

Live: Thursday 27th June 2024, 18:00-19:30 (CEST)

Highlights from the ACC 2024 Congress

ACC 2024 Congress Coverage